JPMorgan Chase & Co. reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 19.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 406,938 shares of the biopharmaceutical company’s stock after selling 98,289 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.67% of Dynavax Technologies worth $8,648,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cubist Systematic Strategies LLC lifted its stake in Dynavax Technologies by 54.5% in the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 3,700 shares during the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in shares of Dynavax Technologies by 16.5% in the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares during the last quarter. Bank of America Corp DE lifted its stake in shares of Dynavax Technologies by 2.3% in the first quarter. Bank of America Corp DE now owns 20,356 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 456 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of Dynavax Technologies by 18.5% in the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares during the last quarter. Finally, Wall Street Access Asset Management LLC acquired a new stake in shares of Dynavax Technologies in the second quarter worth $124,000. Hedge funds and other institutional investors own 70.54% of the company’s stock.

In related news, insider Robert Coffman sold 7,500 shares of the business’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $18.90, for a total transaction of $141,750.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.90% of the company’s stock.

A number of analysts have recently weighed in on DVAX shares. Cowen restated a “buy” rating and issued a $30.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 3rd. Royal Bank of Canada restated a “buy” rating and issued a $26.00 price objective on shares of Dynavax Technologies in a research note on Friday, September 1st. BidaskClub cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. ValuEngine upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, September 7th. Finally, Cantor Fitzgerald started coverage on shares of Dynavax Technologies in a research note on Friday, September 15th. They issued an “overweight” rating and a $24.00 price objective for the company. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $25.17.

Shares of Dynavax Technologies Co. (NASDAQ DVAX) opened at $18.80 on Tuesday. Dynavax Technologies Co. has a one year low of $3.70 and a one year high of $24.45. The firm has a market cap of $1,170.00, a price-to-earnings ratio of -9.59 and a beta of 1.31.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The business had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same quarter in the previous year, the firm posted ($0.90) earnings per share. Dynavax Technologies’s revenue was down 68.8% compared to the same quarter last year. equities research analysts forecast that Dynavax Technologies Co. will post -1.72 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “JPMorgan Chase & Co. Decreases Position in Dynavax Technologies Co. (DVAX)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece on another site, it was stolen and reposted in violation of international copyright legislation. The legal version of this piece can be viewed at https://theolympiareport.com/2017/12/26/jpmorgan-chase-co-decreases-position-in-dynavax-technologies-co-dvax.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.